Form 8-K - Current report:
SEC Accession No. 0001104659-22-059118
Filing Date
2022-05-12
Accepted
2022-05-12 08:34:20
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2215331d1_8k.htm   iXBRL 8-K 28916
2 EXHIBIT 99.1 tm2215331d1_ex99-1.htm EX-99.1 51028
6 GRAPHIC tm2215331d1_ex99-1img001.jpg GRAPHIC 3252
  Complete submission text file 0001104659-22-059118.txt   265799

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA immu-20220512.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE immu-20220512_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE immu-20220512_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2215331d1_8k_htm.xml XML 3598
Mailing Address 665 STOCKTON DRIVE SUITE 300 EXTON PA 19341
Business Address 665 STOCKTON DRIVE SUITE 300 EXTON PA 19341 610-321-3700
Immunome Inc. (Filer) CIK: 0001472012 (see all company filings)

EIN.: 770694340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39580 | Film No.: 22915852
SIC: 2834 Pharmaceutical Preparations